treosulfan has been researched along with Granulocytic Leukemia, Chronic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J | 1 |
| LOEB, V | 1 |
| Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J | 1 |
| Fruehauf, S; Ho, AD; Topaly, J; Zeller, WJ | 1 |
1 trial(s) available for treosulfan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2008 |
3 other study(ies) available for treosulfan and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cell Proliferation; Cyclophosphamide; Drug Interactions; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation Conditioning; Tumor Cells, Cultured | 2014 |
DIHYDROXYBUSULFAN (NSC-39069) IN CHRONIC MYELOCYTIC LEUKEMIA AND MISCELLANEOUS MALIGNANT NEOPLASMS.
Topics: Busulfan; Drug Therapy; Geriatrics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Neoplasms; Toxicology | 1964 |
Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Busulfan; Cell Division; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiotherapy; Tumor Cells, Cultured | 2002 |